bluuebunny/crossref_metadata_2025_split huggingface dataset:
Best Practices in Conventional Core Analysis - A Laboratory Investigation
Authors: Al-Muthana Ahmed S. , Ma S. M. , Okasha Taha 
Published: August 2008

Abstract
Conventional core analysis procedures were investigated to validate data quality and accuracy. In this paper, 23 core samples from wells Q (14 carbonate samples) and N (9 sandstone samples) were tested in the laboratory.
The tests include grain density, porosity, and air and brine permeabilities.
Factors investigated in this study are:∘Effect of equipment calibration on grain density and porosity measurements,∘Effect of drying time on grain density and porosity measurements,∘Effect of sleeve confining pressure on gas permeability measurement, and∘Comparison between gas and liquid permeabilities.
Understanding data acquisition procedures and limitations is very important in core analysis. Therefore, data accuracy in laboratory measurements must be considered. Based on this study, best practices of performing conventional core analysis are recommended.
Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura
Authors: Cataland Spero R. , Jin Ming , Lin Shili , Kraut Eric H. , George James N. , Wu Haifeng M. 
Published: August 2008

AbstractSeveral reports have been published regarding the use of cyclosporine (CSA) in the treatment of idiopathic thrombotic thrombocytopenic purpura (TTP). We hypothesized that prophylactic CSA therapy may prevent recurrences in patients with a history of multiple relapses of TTP. Nineteen patients with idiopathic TTP were enrolled on prospective studies at Ohio State University between September 2003 and May 2007. Patients achieving remission remained on CSA therapy for 6 months, allowing us to evaluate the efficacy of CSA as prophylactic therapy. CSA was administered orally at a dose of 2–3 mg/kg in twice a day divided dose in all patients and continued for a total of 6 months. Long‐term clinical follow‐up with serial analysis of ADAMTS13 biomarkers during and after CSA therapy were performed to evaluate the efficacy of CSA as a prophylactic therapy. 17/19(89%) patients completed 6 months of CSA therapy in a continuous remission. Two patients relapsed during therapy with CSA and seven patients relapsed after discontinuing CSA therapy. Ten patients have maintained a continuous remission a median of 21 months (range, 5–46) after discontinuing CSA. The ADAMTS13 data suggest that CSA resulted in a significant increase in the ADAMTS13 activity during therapy with CSA. 8/9(89%) relapsing patients had severely deficient ADAMTS13 activity (<5%) suggesting this is a significant risk factor for relapse of TTP. These data support the hypothesis that prophylactic CSA improves the ADAMTS13 activity and may be effective at preventing relapses in patients at risk for recurrences of TTP. Am. J. Hematol., 2008. © 2008 Wiley‐Liss, Inc.
Deep subsurface geophysical prospection at Tell Qarqur, Syria
Authors: Casana Jesse , Herrmann Jason T. , Fogel Aaron 
Published: August 2008

AbstractThis paper presents results of recent archaeo‐geophysical investigations utilizing low‐frequency ground‐penetrating radar (GPR) and electrical resistivity tomography (ERT) at the site of Tell Qarqur in western Syria. Like many major tell sites in the Near East, Tell Qarqur possesses archaeological strata more than 30 m in depth and was nearly continuously occupied for 10 000 years. The sheer scale and complexity of tell sites has rendered traditional archaeo‐geophysical methods, designed to map cultural features at 1–2 m below the surface and in only two dimensions, relatively ineffective. The instruments, survey strategies, and processing protocols we have utilized at Tell Qarqur have succeeded in documenting architectural features and archaeological stratigraphy in three dimensions and at much greater depths than has been possible previously. Our results offer new perspectives on the organization and development of settlement at Tell Qarqur and highlight the potential of our methods for archaeo‐geophysical investigations at deeply stratified sites more generally. Copyright © 2008 John Wiley & Sons, Ltd.
An Alternative approach toH∞control for fuzzy systems
Authors: Liu Xiaodong , Liu Wanquan , Li Li , Zhang Qingling , Tong Shaocheng 
Published: August 2008

AbstractIn this paper the problem ofH∞dynamic feedback control for fuzzy dynamic systems has been studied. First the problem ofH∞dynamic feedback controller designs for complex nonlinear systems, which can be represented by Takagi‐Sugeno (T‐S) fuzzy systems, is presented. Second, based on a Lyapunov function, four new dynamic feedbackH∞fuzzy controllers are developed by adequately considering the interactions among all fuzzy sub‐systems and these dynamic feedbackH∞controllers can be obtained by solving a set of suitable linear matrix inequalities. Finally, two examples are given to demonstrate the effectiveness of the proposed design methods. Copyright © 2008 John Wiley and Sons Asia Pte Ltd and Chinese Automatic Control Society
Robust tracking control design for uncertain robotic systems with persistent bounded disturbances
Authors: Tseng Chung‐Shi 
Published: August 2008

AbstractIn this study, a robust nonlinear L∞‐gain tracking control design for uncertain robotic systems is proposed under persistent bounded disturbances. The design objective is that the peak of the tracking error in time domain must be as small as possible under persistent bounded disturbances. Since the nonlinear L∞ ‐gain optimal tracking control cannot be solved directly, the nonlinear L∞ ‐gain optimal tracking problem is transformed into a nonlinear L∞ ‐gain tracking problem by given a prescribed disturbance attenuation level for the L∞ ‐gain tracking performance. To guarantee that the L∞ ‐gain tracking performance can be achieved for the uncertain robotic systems, a sliding‐mode scheme is introduced to eliminate the effect of the parameter uncertainties. By virtue of the skew‐symmetric property of the robotic systems, sufficient conditions are developed for solving the robust L∞ ‐gain tracking control problems in terms of an algebraic equation instead of a differential equation. The proposed method is simple and the algebraic equation can be solved analytically. Therefore, the proposed robust L∞ ‐gain tracking control scheme is suitable for practical control design of uncertain robotic systems. Copyright © 2008 John Wiley and Sons Asia Pte Ltd and Chinese Automatic Control Society
Deployment of a team of biomimetic searching agents based on limited communication quantity
Authors: Jian You‐Ling , Lian Feng‐Li , Lee Hou‐Tsan 
Published: August 2008

AbstractThis paper presents a dispersion movement design for a multi‐agent team inspired by the behavior of creatures. The goal of the dispersion algorithm is to maintain the communication network between agents and to enlarge the coverage area as widely as possible. The communication density, or the number of communication links, is the only information needed. A dispatch rule for releasing agents at a base station is also designed based on the dispersion algorithm. The proposed algorithms have been extensively tested by software simulation. Statistics concerning the coverage area, network partition rate, and spending time are analyzed to verify the feasibility and advantages of the algorithms. Potential applications of the proposed algorithms include rescue in a damaged area, planetary exploration, military reconnaissance, and geophysical mapping. Copyright © 2008 John Wiley and Sons Asia Pte Ltd and Chinese Automatic Control Society
REBUS‐PLS: A response‐based procedure for detecting unit segments in PLS path modelling
Authors: Esposito Vinzi V. , Trinchera L. , Squillacciotti S. , Tenenhaus M. 
Published: August 2008

AbstractStructural equation models (SEMs) make it possible to estimate the causal relationships, defined according to a theoretical model, linking two or more latent complex concepts, each measured through a number of observable indicators, usually called manifest variables. Traditionally, the component‐based estimation of SEMs by means of partial least squares (PLS path modelling, PLS‐PM) assumes homogeneity over the observed set of units: all units are supposed to be well represented by a unique model estimated on the overall data set. In many cases, however, it is reasonable to expect classes made of units showing heterogeneous behaviours to exist.Two different kinds of heterogeneity could be affecting the data: observed and unobserved heterogeneity. The first refers to the case of a priori existing classes, whereas in unobserved heterogeneity no information is available either on the number of classes or on their composition.If a group structure for the statistical units is given, the aim of the analysis is to search for any differences in the behaviours of the a priori given classes. In PLS‐PM this would mean studying the effect of directly observed moderating variables, i.e. estimating as many (local) models as there are classes.Unobserved heterogeneity, instead, implies identifying classes of units (a priori unknown) having similar behaviours. Such heterogeneity is captured by an unobserved (latent) discrete moderating variable defining both the number of classes and the class membership.A new method for unobserved heterogeneity detection in PLS‐PM is proposed in this paper: response‐based procedure for detecting unit segments in PLS‐PM (REBUS‐PLS). REBUS‐PLS, according to PLS‐PM features, does not require distributional hypotheses and may lead to local models that are different in terms of both structural and measurement models. An application of REBUS‐PLS on real data will be shown. Copyright © 2008 John Wiley & Sons, Ltd.
Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule
Authors: Perry James R. , Rizek Philippe , Cashman Rosemary , Morrison Meredith , Morrison Tara 
Published: August 2008

AbstractBACKGROUND.Despite advances in first‐line therapy, there are few data on treatment of glioblastoma multiforme (GBM) at recurrence. Temozolomide (TMZ) is well tolerated and may have activity despite prior TMZ exposure if novel dose schedules are used.METHODS.The authors reviewed their experience with a continuous TMZ schedule (50 mg/m2 daily), given at progression after conventional 5‐day TMZ. Patients were reported in 3 groups: 1) GBM after progression on conventional TMZ; 2) GBM at first recurrence after completion of standard concomitant and adjuvant TMZ; and 3) patients with other anaplastic gliomas at second relapse on conventional TMZ.RESULTS.In Group 1, 21 patients with a median age of 54 years (range, 33 years‐68 years) received a median of 3 cycles (range, 2‐12 cycles) of continuous TMZ at 50 mg/m2. Overall clinical benefit (complete response, partial response, and stable disease) was 47%, with 6‐month progression‐free survival (PFS) of 17%. In Group 2, 14 patients with GBM, median age 52 years (range, 38 years‐62 years) received continuous TMZ at progression after initial TMZ/radiotherapy (RT) and adjuvant TMZ. The median interval after adjuvant TMZ was 3 months (range, 2 months‐10 months). A median of 5 cycles of TMZ was given, and 6‐month PFS was 57%. In Group 3, 14 patients with a median age of 49 years (range, 34 years‐56 years) received continuous TMZ; 2 partial responses and 6 with stable disease were seen, with a 6‐month PFS of 42%. Toxicities were mild and well tolerated; lymphopenia was common but no serious opportunistic infections were identified.CONCLUSIONS.Although retrospective, our results demonstrate that continuous daily administration of TMZ is an active regimen despite prior TMZ therapy. The excellent tolerability of this regimen may allow future combination with other alkylating agents or with novel therapies. Cancer 2008. © 2008 American Cancer Society.
The Preparation of α‐Alkylidene‐γ‐Butyrolactones Using a Telescoped Intramolecular Michael/Olefination (TIMO) Sequence: Synthesis of (+)‐Paeonilactone B
Authors: Edwards Michael G. , Kenworthy Martin N. , Kitson Russell R. A. , Perry Alexis , Scott Mark S. , Whitwood Adrian C. , Taylor Richard J. K. 
Published: August 2008

AbstractA novel telescoped intramolecular Michael addition/proton transfer/HWE olefination sequence has been developed to provide rapid access to α‐alkylidene‐γ‐butyrolactones. This methodology has been applied to prepare a range of tetrahydrobenzofuran‐2,5‐diones, and related systems, and also utilised in an extremely short synthesis of the natural product (+)‐paeonilactone B in enantiomerically pure form. In addition, preliminary experiments are described that illustrate a palladium‐catalysed variant proceeding by way of a π‐allyl intermediate. (© Wiley‐VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2008)
Treatment of hepatocellular carcinoma by AdAFPep/rep, AdAFPep/p53, and 5-fluorouracil in mice
Authors: Sagawa Tamotsu , Yamada Yasuyuki , Takahashi Minoru , Sato Yasushi , Kobune Masayoshi , Takimoto Rishu , Fukaura Junki , Iyama Satoshi , Sato Tsutomu , Miyanishi Koji , Matsunaga Takuya , Takayama Tetsuji , Kato Junji , Sasaki Katsunori , Hamada Hirofumi , Niitsu Yoshiro 
Published: August 2008

Abstract

Although conditionally replicable adenovirus (CRAd) has been used in the clinical treatment of hepatocellular carcinoma (HCC), it suffers from the inherent drawback of having relatively low antitumor activity. Here, we have sought to overcome this drawback. First, we combined CRAd (AdAFPep/Rep) driven by α-fetoprotein enhancer/promoter (AFPep) with a replication-incompetent adenovirus carrying a p53 transgene that is also driven by AFPep. The synergism of this combination produced a significantly improved tumoricidal effect on the human HCC cell line Hep3B, which has a relatively short doubling time in comparison with other human HCC cell lines, through the transactivation of p53 by early region 1A transcribed by AdAFPep/Rep. This synergistic interaction was augmented by the addition of a subtumoricidal dose (0.5 μg/mL) of 5-fluorouracil (5-FU), which enhanced p53 expression and facilitated the release of virions from tumor cells. When relatively large (10-mm-diameter) Hep3B tumors grown in nude mice were injected with the two viruses in combination, they showed significantly impaired growth in comparison with those treated with each virus separately. The growth suppression effect of the virus combination was enhanced by a low dose (600 μg) of 5-FU. Survival of the tumor-bearing mice treated with these three agents was significantly longer than that of control mice. Moreover, the tumor completely disappeared with the repeated injection of these agents.

Conclusion:

This combination strategy holds promise for the treatment of relatively large and rapidly growing HCCs that may be encountered clinically. (Hepatology 2008;48:828–840.)
Of mice and molecular mimicry: Modeling autoimmune hepatitis
Authors: Bowen David G. 
Published: August 2008

Holdener M, Hintermann E, Bayer M, Rhode A, Rodrigo E, Hintereder G, et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med 2008; 205:1409-1422. (Reprinted with permission.)

Abstract
Autoimmune liver diseases, such as autoimmune hepatitis (AIH) and primary biliary cirrhosis, often have severe consequences for the patient. Because of a lack of appropriate animal models, not much is known about their potential viral etiology. Infection by liver-tropic viruses is one possibility for the breakdown of self-tolerance. Therefore, we infected mice with adenovirus Ad5 expressing human cytochrome P450 2D6 (Ad-2D6). Ad-2D6-infected mice developed persistent autoimmune liver disease, apparent by cellular infiltration, hepatic fibrosis, “fused” liver lobules, and necrosis. Similar to type 2 AIH patients, Ad-2D6-infected mice generated type 1 liver kidney microsomal-like antibodies recognizing the immunodominant epitope WDPAQPPRD of cytochrome P450 2D6 (CYP2D6). Interestingly, Ad-2D6-infected wild-type FVB/N mice displayed exacerbated liver damage when compared with transgenic mice expressing the identical human CYP2D6 protein in the liver, indicating the presence of a stronger immunological tolerance in CYP2D6 mice. We demonstrate for the first time that infection with a virus expressing a natural human autoantigen breaks tolerance, resulting in a chronic form of severe, autoimmune liver damage. Our novel model system should be instrumental for studying mechanisms involved in the initiation, propagation, and precipitation of virus-induced autoimmune liver diseases.
Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population
Authors: Ma Zhiyong , Tsuchiya Norihiko , Yuasa Takeshi , Inoue Takamitsu , Kumazawa Teruaki , Narita Shintaro , Horikawa Yohei , Tsuruta Hiroshi , Obara Takashi , Saito Mitsuru , Satoh Shigeru , Ogawa Osamu , Habuchi Tomonori 
Published: August 2008

AbstractFibroblast growth factor receptor 4 (FGFR4) is a member of a family of transmembrane receptors with ligand‐induced tyrosine kinase activity. The Glycine (Gly) to Arginine (Arg) polymorphism at codon 388 (Gly388Arg), which encodes an amino acid in the transmembrane part of the FGFR4 gene, was reported to be associated with an increased risk in some carcinomas. We investigated the association between the Gly388Arg polymorphism or the G or A polymorphism at intron 11 (rs2011077) of FGFR4, which was located 1,213 base pairs apart from the Gly388Arg polymorphism, and the risk of prostate cancer or benign prostate hyperplasia (BPH), and the prostate cancer disease status in Japanese men. Genotypes of Gly388Arg and rs2011077 polymorphisms of FGFR4 were determined in 492 patients with prostate cancer, 165 patients with BPH and 179 male controls. Regarding the Gly388Arg polymorphism, individuals with the ArgArg genotype had a 2.207‐ and 1.958‐fold increased risk of prostate cancer and BPH, and a 1.804‐fold increased risk of metastatic prostate cancer compared with those with the GlyGly genotype. Regarding the rs2011077 polymorphism, individuals with the GG genotype had a 6.260‐ and 3.033‐fold increased risk of prostate cancer and BPH, and a 5.550‐fold increased risk of metastatic prostate cancer compared with those with the AA genotype. Our results indicate that the FGFR4 Arg allele of the Gly388Arg polymorphism and the G allele of the rs2011077 polymorphism have a significant impact on the development of prostate cancer and BPH, and the progression of prostate cancer in a Japanese population. © 2008 Wiley‐Liss, Inc.
Hesperidin, an antioxidant flavonoid, prevents acrylonitrile‐induced oxidative stress in rat brain
Authors: El‐Sayed El‐Sayed M. , Abo‐Salem Osama M. , Abd‐Ellah Mohamed F. , Abd‐Alla Gamil M. 
Published: August 2008

AbstractAcrylonitrile (ACN) is a volatile, toxic liquid used as a monomer in the manufacture of synthetic rubber, styrene plastics, acrylic fiber, and adhesives. ACN is a potent neurotoxin. A role for free radical mediated lipid peroxidation in the toxicity of ACN has been suggested. We examined the ability of hesperidin, an antioxidant flavonoid, to attenuate ACN‐induced alterations in lipid peroxidation in rat brains. The daily oral administration of ACN to male albino rats in a dose of 50 mg/kg bwt for a period of 28 days produced a significant elevation in brain lipid peroxides measured as malondialdehyde (MDA) amounting to 107%, accompanied by a marked decrease in brain‐reduced glutathione (GSH) content reaching 63%. In addition, ACN administration resulted in significant reductions in the enzymatic antioxidant parameters of brain; superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH‐Px), and glutathione‐S‐transferase (GST) recording 43%, 64%, 52%, and 43%, respectively. On the other hand, pretreatment with hesperidin and its coadministration with ACN once daily in a dose of 200 mg/kg bwt i.p. for 28 days ameliorated ACN‐induced alterations in brain lipid peroxidation. These results suggest that hesperidin may have a beneficial role against ACN‐induced oxidative stress in the brain; an effect that is mainly attributed to the antioxidant property of hesperidin. © 2008 Wiley Periodicals, Inc. J Biochem Mol Toxicol 22:268–273, 2008; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/jbt.20237
Translation elongation factor eEF1A binds to a novel myosin binding protein‐C‐like protein
Authors: Mansilla Francisco , Dominguez Carlota A.G. , Yeadon James E. , Corydon Thomas J. , Burden Steven J. , Knudsen Charlotte R. 
Published: August 2008

AbstractEukaryotic translation elongation factor 1A (eEF1A) is a guanine‐nucleotide binding protein, which transports aminoacylated tRNA to the ribosomal A site during protein synthesis. In a yeast two‐hybrid screening of a human skeletal muscle cDNA library, a novel eEF1A binding protein, immunoglobulin‐like and fibronectin type III domain containing 1 (IGFN1), was discovered, and its interaction with eEF1A was confirmed in vitro. IGFN1 is specifically expressed in skeletal muscle and presents immunoglobulin I and fibronectin III sets of domains characteristic of sarcomeric proteins. IGFN1 shows sequence and structural homology to myosin binding protein‐C fast and slow‐type skeletal muscle isoforms. IGFN1 is substantially upregulated during muscle denervation. We propose a model in which this increased expression of IGFN1 serves to down‐regulate protein synthesis via interaction with eEF1A during denervation. J. Cell. Biochem. 105: 847–858, 2008. © 2008 Wiley‐Liss, Inc.
Involvement of AMP‐activated protein kinase and p38 mitogen‐activated protein kinase in 8‐Cl‐cAMP‐induced growth inhibition
Authors: Han Jee Hae , Ahn Young‐Ho , Choi Ki‐Young , Hong Seung Hwan 
Published: August 2008

Abstract8‐Cl‐cAMP (8‐chloro‐cyclic AMP), which induces differentiation, growth inhibition and apoptosis in various cancer cells, has been investigated as a putative anti‐cancer drug. Although we reported that 8‐Cl‐cAMP induces growth inhibition via p38 mitogen‐activated protein kinase (MAPK) and a metabolite of 8‐Cl‐cAMP, 8‐Cl‐adenosine mediates this process, the action mechanism of 8‐Cl‐cAMP is still uncertain. In this study, it was found that 8‐Cl‐cAMP‐induced growth inhibition is mediated by AMP‐activated protein kinase (AMPK). 8‐Cl‐cAMP was shown to activate AMPK, which was also dependent on the metabolic degradation of 8‐Cl‐cAMP. A potent agonist of AMPK, 5‐aminoimidazole‐4‐carboxamide ribonucleoside (AICAR) could also induce growth inhibition and apoptosis. To further delineate the role of AMPK in 8‐Cl‐cAMP‐induced growth inhibition and apoptosis, we used two approaches: pharmacological inhibition of the enzyme with compound C and expression of a dominant negative mutant (a kinase‐dead form of AMPKα2, KD‐AMPK). AICAR was able to activate p38 MAPK and pre‐treatment with AMPK inhibitor or expression of KD‐AMPK blocked this p38 MAPK activation. Cell growth inhibition was also attenuated. Furthermore, p38 MAPK inhibitor attenuated 8‐Cl‐cAMP‐ or AICAR‐induced growth inhibition but had no effect on AMPK activation. These results demonstrate that 8‐Cl‐cAMP induced growth inhibition through AMPK activation and p38 MAPK acts downstream of AMPK in this signaling pathway. J. Cell. Physiol. 218: 104–112, 2009. © 2008 Wiley‐Liss, Inc.